These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1909700)

  • 1. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
    Fukuoka M; Negoro S; Masuda N; Furuse K; Kawahara M; Kodama N; Ikegami H; Nakamura S; Nishio H; Ohnoshi T
    J Cancer Res Clin Oncol; 1991; 117(5):473-8. PubMed ID: 1909700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Falkson CI; Falkson HC; Falkson G
    Invest New Drugs; 1989 Jul; 7(2-3):261-7. PubMed ID: 2507474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W; Klein HO; Brock N; Burkert H; Günther U; Hoefer-Janker H; Mitrenga D; Schnitker J; Voigtmann R
    Cancer Treat Rep; 1979 Mar; 63(3):501-5. PubMed ID: 106965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide with mesna uroprotection in the management of lung cancer.
    Holoye PY; Glisson BS; Lee JS; Dhingra HM; Murphy WK; Umsawasdi T; Levy JK; Jeffries D; Raber MN; Hong WK
    Am J Clin Oncol; 1990 Apr; 13(2):148-55. PubMed ID: 2156418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The protective effect of 2-mercapto-ethane sulfonate (MESNA) on hemorrhagic cystitis induced by high-dose ifosfamide treatment tested by a randomized crossover trial.
    Sakurai M; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Tamura T; Sano T; Suemasu K; Jett JR
    Jpn J Clin Oncol; 1986 Jun; 16(2):153-6. PubMed ID: 3090314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
    Schnitker J
    Arzneimittelforschung; 1982; 32(10):1334-8. PubMed ID: 6817761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
    Munshi NC; Loehrer PJ; Williams SD; Langefeld C; Sledge G; Nichols CR; Roth BJ; Neuman A; Walsh WB; Einhorn LH
    Invest New Drugs; 1992 Aug; 10(3):159-63. PubMed ID: 1428725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
    Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
    J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552.
    Case DC; Anderson J; Ervin TJ; Gottlieb A
    Med Pediatr Oncol; 1988; 16(3):182-6. PubMed ID: 3132591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose ifosfamide with mesna uroprotection.
    Cerny T
    Pathol Biol (Paris); 1993 Jan; 41(1):102. PubMed ID: 8316441
    [No Abstract]   [Full Text] [Related]  

  • 13. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
    Lokich I; Anderson N; Bern M; Moore C
    Cancer; 1991 Feb; 67(4):883-5. PubMed ID: 1899352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral administration of mesna with ifosfamide.
    Goren MP
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):91-6. PubMed ID: 8677457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide and mesna in epithelial ovarian carcinoma.
    Sutton G
    Gynecol Oncol; 1993 Oct; 51(1):104-8. PubMed ID: 8244163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
    Kurowski V; Wagner T
    Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of mesna to prevent ifosfamide-induced urotoxicity.
    Siu LL; Moore MJ
    Support Care Cancer; 1998 Mar; 6(2):144-54. PubMed ID: 9540174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Barrett RJ; McGehee R
    Am J Obstet Gynecol; 1992 Feb; 166(2):556-9. PubMed ID: 1536229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Schütte J; Kellner R; Seeber S
    Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.